Product Description
For Advanced Malignant Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05162469)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20213194 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |